Preceding Infection and Risk of Stroke: An Old Concept Revived by the COVID-19 Pandemic by McCulloch, Laura
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preceding Infection and Risk of Stroke: An Old Concept Revived
by the COVID-19 Pandemic
Citation for published version:
McCulloch, L 2020, 'Preceding Infection and Risk of Stroke: An Old Concept Revived by the COVID-19
Pandemic', International Journal of Stroke. https://doi.org/Anecdotal reports and clinical observations have
recently emerged suggesting a relationship between COVID-19 disease and stroke; highlighting the
possibility that infected individuals may be more susceptible to cerebrovascular events. In this review we
draw on emerging studies of the current pandemic and data from earlier, viral epidemics, to describe
possible mechanisms by which SARS-CoV-2 may influence the prevalence of stroke, with a focus on the
thromboinflammatory pathways, which may be perturbed. Some of these potential mechanisms are not
novel but are, in fact, long-standing hypotheses linking stroke with preceding infection that are yet to be
confirmed. The current pandemic may present a renewed opportunity to better understand the relationship
between infection and stroke and possible underlying mechanisms.
Digital Object Identifier (DOI):
Anecdotal reports and clinical observations have recently emerged suggesting a relationship between COVID-19
disease and stroke; highlighting the possibility that infected individuals may be more susceptible to
cerebrovascular events. In this review we draw on emerging studies of the current pandemic and data from
earlier, viral epidemics, to describe possible mechanisms by which SARS-CoV-2 may influence the prevalence
of stroke, with a focus on the thromboinflammatory pathways, which may be perturbed. Some of these potential
mechanisms are not novel but are, in fact, long-standing hypotheses linking stroke with preceding infection that
are yet to be confirmed. The current pandemic may present a renewed opportunity to better understand the
relationship between infection and stroke and possible underlying mechanisms.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
International Journal of Stroke
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Sep. 2020
Peer Review Version
Preceding Infection and Risk of Stroke: 
An Old Concept Revived by the COVID-19 Pandemic 
Journal: International Journal of Stroke
Manuscript ID IJS-06-20-8156.R1
Manuscript Type: Review
Date Submitted by the 
Author: 26-Jun-2020
Complete List of Authors: South, Kieron; The University of Manchester, 
International Journal of Stroke
DOI: 10.1177/1747493020943815
Peer Review Version
McCulloch, Laura; The University of Edinburgh Centre for Discovery Brain 
Sciences, UK Dementia Research Institute at University of Edinburgh
McColl, Barry; The University of Edinburgh Centre for Discovery Brain 
Sciences, UK Dementia Research Institute at University of Edinburgh
Elkind, Mitchell; Columbia University, Neurology
Allan, Stuart; University of Manchester, Faculty of Life Sciences
Smith, Craig; Greater Manchester Comprehensive Stroke Centre, Medical 
Neurosciences; Institute of Cardiovascular Sciences, Stroke and Vascular 
Research Centre
Keywords: Ischaemic stroke, Vascular events, Stroke prevalence, Risk factors, COVID-19, Infection, SARS-CoV-2
Page 1 of 21
International Journal of Stroke
DOI: 10.1177/1747493020943815
Peer Review Version
Figure 1. Thromboinflammatory pathways implicated in the pathophysiology of COVID-19 and complicating 
ischaemic stroke. Infection of the lower respiratory tract begins with the binding of SARS-CoV-2 to 
angiotensin converting enzyme 2 (ACE2) on the surface of type II alveolar pneumocytes (1). The immediate 
type I interferon response recruits macrophages, monocytes and neutrophils to the alveoli. Propagation of 
the innate immune response is directed by Th1 and Th17 CD4+ T cells (2) as neutrophils and pro-
inflammatory monocytes are targeted to the site of infection (3). Endothelial activation, by either the 
inflammatory environment or by direct viral infection, upregulates key cell adhesion molecules allowing 
further infiltration of pro-inflammatory monocytes, cytotoxic T cells and activated neutrophils (4). 
 Endothelial activation also elicits tissue factor release, endovascular recruitment of neutrophils releasing 
neutrophil extracellular traps (NETs) (4) and von Willebrand factor (VWF) exocytosis from Weibel Palade 
bodies (5) all of which contribute to the development of microvascular thrombosis. These local immune and 
pro-coagulant responses may result in systemic release of multiple cytokines and chemokines and ultra 
large VWF multimers, hyper-activation of circulating platelets and the embolization of VWF/platelet-rich 
thrombi (6). Increased pro-inflammatory and pro-coagulant factors in the plasma could be sufficient for in 
situ thrombus formation in the cerebral vasculature (7) and this may be exacerbated by infection and/or 
activation of the cerebral endothelium and local release of VWF and tissue factor (8). Endothelial activation 
would be expected to facilitate recruitment of neutrophils, monocytes and macrophages to the vessel lumen 
and induce a local inflammatory response in the surrounding brain parenchyma thereby polarising microglia 
(9). Small vessel occlusion, by thromboemboli or by in situ thrombosis due to endothelial dysfunction, 
causes hypoperfusion of brain tissue (10). Ultimately, this combination of tissue hypoperfusion and the pro-
inflammatory action of infiltrating and brain resident immune cells is the origin of stroke brain injury (11). 
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Abstract
Anecdotal reports and clinical observations have recently emerged suggesting a relationship 
between COVID-19 disease and stroke; highlighting the possibility that infected individuals may be 
more susceptible to cerebrovascular events. In this review we draw on emerging studies of the 
current pandemic and data from earlier, iral epidemics, to describe possible mechanisms by which 
SARS-CoV-2 may influence the prevalence of stroke, with a focus on the thromboinflammatory 
pathways, which may be perturbed. Some of these potential mechanisms are not novel but are, in 
fact, long-standing hypotheses linking stroke with preceding infection that are yet to be confirmed. 
The current pandemic may present a renewed opportunity to better understand the relationship 
between infection and stroke and possible underlying mechanisms.
Introduction
The SARS-CoV-2 Global Pandemic
At the time of writing, the global number of confirmed SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) cases is approaching 9 million, with over 470,000 reported fatalities. The 
current novel coronavirus outbreak began to receive worldwide media attention in early January 
2020 with the earliest cluster of cases traced back to December 2019 i  the city of Wuhan in China. 
By the 30th of January the World Health Organisation (WHO) declared the outbreak a ‘public health 
emergency of international concern’ and, after cases were reported in 210 countries, the outbreak 
was recognised by WHO as a pandemic on 11th March 2020. 
SARS-CoV-2 is a member of the betacoronavirus genus of the coronaviridae family of enveloped, 
single-stranded RNA viruses, several of which are known to cause mild respiratory disease in 
humans. It was named because of its similarity to SARS-CoV, the virus responsible for an epidemic in 
2002-03 that infected approximately 8000 people with almost 800 fatalities. Both SARS-CoV and 
SARS-CoV-2 cause acute respiratory symptoms but due to enhanced rates of transmission derived 
from transmission from asymptomatic individuals1and a high level of early viral shedding in the 
upper respiratory tract2, this recent pandemic has attained a large global impact.
Angiotensin-converting enzyme 2 (ACE2), the ‘receptor’ for host cell entry of SARS-CoV-23, is most 
prominently expressed on the surface of lung alveolar epithelial cells, venous and arterial 
endothelial cells, arterial smooth muscle cells and enterocytes of the small intestine4. Notably, 
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considering the possible neurotropism of SARS-CoV-2 discussed later, ACE2 is also found on cardio-
respiratory neurons of the brainstem, in the hypothalamus and the motor cortex5. There is evidence 
that SARS-CoV (and possibly SARS-CoV-2) is able to infect lymphocytes, monocytes and lymphoid 
tissues6. This tissue distribution is a critical determinant of the COVID-19 disease course and may 
drive some of the thromboinflammatory alterations that might influence stroke pathophysiology, as 
discussed in this review. 
Clinical Presentation of COVID-19
Unlike its predecessor SARS, COVID-19 manifests as a broad spectrum of disease severity from a 
completely asymptomatic state of infection, through mild flu-like symptoms, to the life-threatening 
acute respiratory distress syndrome (ARDS). It has been estimated that as many as 86% of cases in 
China were asymptomatic or mildly symptomatic and were, therefore, undocumented1. The 
multitude of factors contributing to this disparity in disease severity are not yet fully understood and 
are likely to include genetic, environmental and host response factors and would, therefore, be 
outside the scope of this review. However, it is already clear that disease progression is, to some 
extent, linked to viral load7, age, sex, ethnicity and comorbidity8, 9.
At onset of illness the most common symptoms are fever, cough, myalgia, anosmia and fatigue. 
Common chest radiological findings are bilateral ground-glass opacity, interlobular septal thickening, 
and thickening of the pleura10. In patients who went on to develop ARDS, pleural effusion, 
lymphadenopathy and round cystic changes were also observed, similar to those seen previously in 
SARS11, Middle East respiratory Syndrome (MERS)12 and H5N1 influenza13. Patients that develop ARDS 
experience severe hypoxemia, and the leading causes of mortality are respiratory failure, heart 
failure, fulminant myocarditis and multiple organ failure. 
Cerebrovascular Complications in COVID-19 Patients
The possible relationship between respiratory tract infection and the incidence of stroke, particularly 
ischaemic stroke, is not a new concept. Early case-control studies identified respiratory tract 
infections as a significant risk factor across all age groups despite adjusting for other known vascular 
risk factors14. A large case-series analysis of UK medical records identified a significant risk of either 
first stroke or recurrent stroke associated with a diagnosis of acute respiratory tract infection15. This 
risk was highest in the first few days after infection, steadily declining thereafter but remaining 
elevated over baseline for some time. The incidence ratio of first stroke was found to be 3.19 (95% 
CI 2.81 to 3.62) within three days of infection and 2.09 (95% CI 1.89 to 2.32) within 14 days. A later 
retrospective case-crossover study of administrative data in the US, focussing on respiratory tract 
infections defined using Centers for Disease Control and Prevention criteria as ‘influenza-like illness’, 
identified a similar risk of ischaemic stroke within 15 days of infection (Odds Ratio 2.88, 95% CI 1.86 
to 4.47)16. 
Large, systematically collated datasets are not yet available for the current SARS-CoV-2 pandemic 
and, as such reliable estimates of the associated risk of stroke have not yet been published. This is 
also true of the previous SARS pandemic that only affected 8000 individuals. Although, an 
approximate stroke incidence rate of 1 per 42 SARS patients was determined from a small, 
retrospective single-centre analysis17. For now, assumptions on the prevalence of stroke amongst 
COVID-19 patients are based on small, single centre observational studies18, which estimate an 
incidence rate of approximately 5% amongst the most severe cases. In a larger single centre study of 
3556 COVID-19 patients the estimated stroke incidence rate was much lower at 0.9%19.
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It is likely that any estimation of stroke incidence will be confounded by under-reporting; both in 
severe infection with competing risk of mortality and milder infections (and strokes) not presenting 
to hospital or primary care. 
Common Features of COVID-19 Pathogenesis and Early Pathology of Ischaemic Stroke
As we begin to better understand COVID-19 there are clearly aspects of its pathogenesis and disease 
course that are implicated in the initiation, or in the very early pathophysiology, of ischaemic stroke. 
What follows herein is a detailed summary of the current literature surrounding COVID-19, 
encompassing the immune and inflammatory responses to infection, thrombotic manifestations and 
vascular consequences of infection with a focus on possible mechanisms by which these elements 
may contribute to acute stroke events. 
The Immune Response to SARS-CoV-2 Infection
We know, from extensive research on SARS-CoV and other RNA viruses, that initial virus recognition 
occurs in the ciliated epithelial cells of the upper respiratory tract. This leads to activation of type II 
alveolar pneumocytes and innate immune cells, culminating in the activation of type I Interferon 
(IFN), production of pro-inflammatory cytokines (interleukin-6 [IL-6], Tumor Necrosis Factor [TNF]) 
and the induction of IFN-stimulated genes20 (Figure 1.1).  
The immediate immunomodulatory impact of type 1 IFN (and the subsequent type 2 IFN (IFN-γ) 
response) manifests as an accumulation of pro-inflammatory monocytes and macrophages in the 
alveoli21,. Recruited macrophages are themselves prominent sources of IL-6, monocyte 
chemoattractant protein (MCP)-1 (CCL2), IL-8 and IFN22, thereby contributing to further influx of 
myeloid cells (Figure 1.1), including neutrophils, which are an indispensable component of the 
inflammatory response to infection but also a major contributor to lung pathology23. Extensive 
neutrophil extravasation into the alveolar space has been identified in post-mortem tissue of COVID-
19 patients24 and neutrophil activation has long been associated with disease pathologies involving 
ARDS, and correlates with the extent of lung damage and with cytokine levels (TNFα, IL-6 and IL-8)25. 
The release of pro-inflammatory cytokines (type I IFN and IL-6) also aids the initiation of the adaptive 
immune response to viral infection, through the maturation of lung resident conventional or 
monocyte-derived dendritic cells (DCs) 26.These DC’s migrate to draining lymph nodes and elicit a 
robust activation and proliferation of naïve, antigen-specific CD8+ (“cytotoxic”) T cells and naive CD4+ 
(“helper”) T cells27. In a cohort of 128 SARS patient samples, a high frequency of , CD8+ T cells, Th1  
and Th2 CD4+ T cells and polyfunctional CD4+ T cells, were identified in blood from patients with 
severe disease28. Early indications from COVID-19 patients suggest a similar clonal expansion of CD4+ 
and CD8+ T cells29, and differentiation of Th1 30 and  Th17 cells31.
A paradoxical, but common, characteristic of SARS-CoV-2 infection is the development of 
lymphopenia, observed also in the SARS-CoV, MERS-CoV and H1N1/H7N9 influenza pandemics32. In 
COVID-19 patients a marked decrease in the number of peripheral CD4+ and CD8+ T cells, 
accompanied by hyperactivity of these populations31, has been suggested as an effective predictor of 
disease severity33. It has been postulated that this may be the result of virus-mediated dysfunction 
of lymphatic tissues, cytokine-mediated lymphocyte apoptosis or the direct killing of lymphocytes by 
viral infection6. It could also be, simply, the redistribution of lymphocytes to the infected tissue 
and/or lymph nodes.
The net result of lymphopenia, particularly in combination with enhanced granulocytosis, is an 
increase in the neutrophil to lymphocyte ratio (NLR). Increased NLR is already evident in COVID-19 
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cohorts and has been suggested as a potential prognostic marker of more severe illness and 
increased risk of mortality34. This is an important observation given that NLR also has prognostic 
value for determining stroke risk35.
The Exaggerated Immune Response (‘The Cytokine Storm’) 
The cumulative consequence of leukocyte recruitment and activation is the accumulation of 
cytokines, both in the lung tissue and in the circulation. In severe COVID-19 patients this response is 
exaggerated, resulting in a ‘cytokine storm’, in which aberrant cytokine expression and 
disproportionate inflammation results in persistent acute lung injury extending beyond the time of 
peak viral load. Cell populations of particular relevance to the development of a cytokine storm are 
pro-inflammatory (CD14+, CD16+, IL-6hi) monocytes and pathogenic (GM-CSF+, IFN-γ+) Th1 
lymphocytes, which appear to predominate in the circulation of COVID-19 patients in ICU30, and 
Th17 lymphocytes which are prevalent in influenza36. Together these cells propagate a second wave 
of immune cell infiltration30, polarisation of lung-resident macrophages to a pro-inflammatory 
phenotype37 and cytokine production (Figure 1.2 and 1.3). 
Macrophage polarisation rapidly elevates the levels of circulating cytokines, most notably IL-6 
(Figure 1.6). In all of the COVID-19 cohorts included in a recent meta-analysis, IL-6 levels were 
significantly elevated (approximately 3 fold) in patients with complicated disease compared to those 
with non-complicated disease38. In the largest of the individual studies (n=452) the median plasma 
concentration of IL-6 was 25.5 pg/ml39, in line with levels observed in severe SARS-CoV40 and MERS-
CoV infection41. 
The exaggeration of peripheral immune responses and ensuing inflammation is likely to be one of 
the key aspects of COVID-19 pathogenesis that could result in cerebrovascular events. This is 
highlighted by the observation that IL-6 is a predictor of stroke risk42. It is possible that 
hyperinflammation may contribute to the progression of two key stroke risk factors, atherosclerosis 
and atrial fibrillation (AF). In the case of chronic atherosclerosis, viral infection is thought to drive the 
progression of atheromatous plaques through enhanced macrophage and T-cell responses43 within 
the developing lesion, although this may not occur within a timeframe that is relevant to COVID-19 
related stroke. However, the release of IFN-γ, TNF-α and other destabilising factors can then expose 
the plaque’s thrombogenic core44 inducing plaque rupture which is more likely to be influenced by 
acute inflammatory conditions. There is also some evidence that plaque development and rupture is 
influenced directly by viral infection of vascular cells45. Similarly, peripheral immune responses to 
viral infections are thought to contribute to the pathogenesis of AF through the release of reactive 
oxygen species and myeloperoxidases from neutrophils and the local release of TNF-α and IL-1β 
from macrophages46. Viral infection may also be an important factor in the development of non-
valvular AF through upregulation of monocyte TLR2 and IL-6 release47.
Thrombotic Complications of COVID-19
COVID-19 appears to share many aspects of its pathology with previous viral pandemics including 
the prevalence of thrombotic complications. During the 2009 H1N1 influenza pandemic the incidence 
of overt thrombotic manifestations (deep vein thrombosis [DVT] or pulmonary embolism [PE]) was 
approximately 6%48. During the 2002-2003 SARS pandemic the incidence of DVT was estimated to be 
as high as 20% with a further 11% of patients developing PE49. In a larger SARS cohort thrombotic 
abnormalities were identified in over 60% of patients50. Studies of aberrant coagulation in COVID-19 
patients are often reporting on small cohorts and conclusions have been conflicting. In a cohort of 
183 patients with severe COVID-19, haemostatic abnormalities were associated with fatality, with 
Page 7 of 21
International Journal of Stroke
DOI: 10.1177/1747493020943815
Peer Review Version
6
70% of non-survivors meeting the criteria for disseminated intravascular coagulation (DIC), including 
a progressive increase in PT and D-dimer 51. However, in a smaller cohort of ICU patients a state of 
hypercoagulability, not consistent with overt DIC (increased D-dimer without associated bleeding), 
was reported indicating extensive pulmonary vascular thrombosis52. This is further supported by a 
small autopsy series which identified thrombotic microangiopathy that was completely restricted to 
the lungs24.
It is, therefore, still unclear if SARS-CoV-2 infection has a direct impact on haemostatic mechanisms 
or whether the thrombotic manifestations are purely the result of DIC, secondary to systemic 
inflammation, or sepsis-induced coagulopathy. There is some emerging consensus regarding the rate 
of incidence of venous thrombosis (in the absence of overt DIC) in COVID-19 patients, and it is 
extraordinarily high. Klok et al. recorded an incidence of total thrombotic complications of 31% 
(95%CI 20-41%, n=184), of which 81% were PE53. The incidence of unspecified venous thrombosis in 
two smaller studies was 25% (n=81)54 and 69% (n=26)55. In a larger cohort of patients (n=362) the 
incidence of thromboembolic events was 16.7% in ICU patients and 6.4% across all COVID-19 
patients in general wards56. In all of these studies the incidence of VTE is despite all patients having 
received, at least, a prophylactic dose of anticoagulants. 
There is clear evidence, from post-mortem lung pathology, of extensive thrombosis in the alveolar 
capillaries and small vessels in response to COVID-19 infection24. The composition of these thrombi 
includes fibrin deposits, platelet aggregates, CD4+ cell aggregates and partially degenerated 
neutrophils (Figure 1.4). Fibrin deposition in response to inflammation is initially driven by elevated 
C-reactive protein (CRP) and inflammatory cytokines57, 58. Local tissue factor release, generating
thrombin, coupled with elevated plasma concentrations of fibrinogen59 results in deposition of fibrin
which persists due to the concomitant suppression of fibrinolysis by CRP-mediated release of
plasminogen activator inhibitor-1 (PAI-1)60 and thrombin activatable fibrinolysis inhibitor (TAFI)61.
Any other pro-coagulant and/or anti-coagulant factors that may be specifically influenced by SARS-
CoV-2, thereby further contributing to the hypercoagulable state, are not yet known and, as most
are synthesised in the liver, it may be unlikely that infection will alter their transcription. A
comprehensive analysis of the plasma concentrations of coagulation factors in patients with COVID-
19, or indeed any viral infection, seems to be lacking at present from the literature.
The presence of platelet-containing thrombi in the lungs of COVID-19 patients indicates the 
involvement of other thromboinflammatory pathways that upregulate endothelial platelet 
recruitment and aggregation (Figure 1.5). This is likely to be initiated by an increase in IL-6, IL-8 and 
TNF-α which stimulate the exocytosis of von Willebrand factor (VWF) from Weibel-Palade bodies62. 
The VWF strings released unfold under rheological shear forces and capture platelets through the 
glycoprotein (GP) Ib-IX-V complex, a process down-regulated by the protease ADAMTS13. The 
synthesis of ADAMTS13 is known to be inhibited by IFN-γ, IL-4 and TNF-α and, through an as yet 
unknown mechanism, IL-6 inhibits ADAMTS13 activity at the endothelium 62, 63. Therefore, under 
inflammatory conditions, there is an amplification of VWF-mediated platelet capture. As an acute 
phase reactant, VWF (particularly ultra large VWF multimers) has long been associated with acute 
inflammation64 and acute viral infection of the respiratory tract65, 66. It is also highly likely that 
VWF/ADAMTS13 imbalance plays an important role in COVID-induced thrombosis with some small 
studies already identifying VWF antigen and VWF activity in COVID-19 patients as high as 600-800% 
of the normal range 67, 68. Notably, an imbalance in the VWF/ADAMTS13 axis is an established risk 
factor for the incidence of ischaemic stroke69 and is already implicated in stroke complicating other 
viral infections70.
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The formation of platelet-rich thrombi could be further exacerbated by a local hyper-activation of 
platelets, the consumption of which would account for mild thrombocytopenia observed in many 
COVID-19 patients and linked to higher rates of mortality71. Platelet activation and aggregation is 
likely to be induced by the action of locally generated thrombin through PAR1/PAR4 signalling on 
platelets. The recruitment of platelets from the circulation may also be supplemented by local 
production of platelets by pulmonary megakaryocytes. These have been observed, in post-mortem 
lung pathology, actively producing platelets in the alveolar capillaries24. The significance of platelets 
in COVID-19 pathology is highlighted by the possible therapeutic benefit of anti-platelet therapies72. 
Importantly, platelet activation and subsequent degranulation may be an early contributor to the 
exacerbated immune/inflammatory response to SARS-CoV-2 infection through numerous mediators 
of leukocyte and endothelial function73. Platelet recruitment of leukocytes to the developing 
thrombus would explain the notable presence of CD4+ T cell aggregates24 and neutrophil 
extracellular traps,74 both of which further contribute to both the pro-inflammatory and pro-
coagulant environment. 
Recently it has become apparent that stroke-causing thrombi are often rich in VWF, platelets, 
leukocytes and NETs and that this composition is associated with t-PA resistance 75. Formation of 
thrombi with this composition requires the upregulation of multiple thromboinflammatory 
components, many of which (described above) are influenced by COVID-19. This, together with the 
incontrovertible role of hyper-coagulation in ischaemic stroke pathology76, forms perhaps the 
strongest argument for a causative link between COVID-19 and stroke. 
Vasculitis and Endothelial Dysfunction
Emerging evidence suggests that COVID-19 pathology may be considered, at least in part, a vascular 
disease and that the effects of SARS-CoV-2 on endothelial function may go beyond the release of 
tissue factor and VWF already described77. ACE2 is expressed in venous and arterial endothelial cells, 
arterial smooth muscle cells and pericytes4. A recent post-mortem case series has indicated that 
SARS-CoV-2 is capable of productively infecting and damaging endothelial cells across multiple tissue 
beds (Figure 1.4 and 1.8), although, the authors concede that these observations are not 
conclusive78. Hyperactivation of the endothelium during viral infection is known to induce the loss of 
tight junctions, vessel permeability and, subsequently, pulmonary haemorrhage and alveolar 
edema79. In the later stages of COVID-19 progression, as the disease becomes more severe, it is 
possible that complement activation may also contribute to vasculitis. This mechanism has been 
observed previously in animal models of coronavirus infection80 and pulmonary biopsies from a 
small number of COVID-19 patients indicate the presence of complement activation81. In addition to 
inflammation of the vessel wall, complement may contribute to vascular dysfunction through the 
initiation of microvascular thrombosis. All of these processes could be expected to occur in the 
endothelium of multiple organs, including the brain, where alterations of the vascular environment 
are a key contributor to the development of ischaemic brain injury.
Systemic Implications of SARS-CoV-2 Infection
It is not yet fully understood how systemic SARS-CoV-2 infection, or systemic effects of COVID-19 
disease, affects other organs and tissues. In the context of stroke, the possibility of CNS infiltration 
by the virus, infection and/or dysfunction of the cerebral vasculature and a systemic hyper-
inflammatory and pro-coagulant state are of particular interest. 
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The possibility of SARS-CoV-2 neurotropism is intriguing. Many other viruses, including 
coronaviruses, are capable of infecting CNS related cell types including neurons, microglia, 
astrocytes and oligodendrocytes. In COVID-19 patients, CNS infection may account for the high 
incidence of neurological manifestations (as high as 88% of severe cases82) which include headaches, 
nausea, impaired consciousness, acute cerebrovascular disease and seizures83. Conversely, these 
manifestations may simply reflect the remote effects of systemic inflammation. A likely route of CNS 
infiltration is through peripheral nerve terminals, particularly the olfactory bulb. In a humanised 
mouse model of SARS-CoV-1 infection, nasal inoculation was followed by dissemination of the virus 
from the olfactory epithelium to the axons of the olfactory bulb, through the pyriform cortex to the 
brain stem84. This may also explain the widespread incidence of anosmia occurring in COVID-19 
cohorts. There is a strong association between acute CNS infection (e.g. meningitis) and the 
incidence of stroke85 thought to result from vasculitis and a related hyper-coagulant state.
In the case of systemic thrombosis, an important distinction yet to be made is whether all 
thrombotic events are originating in a pro-coagulant micro-environment within the lungs or if there 
is a systemic pro-coagulant state facilitating in situ thrombus formation in the brain or embolism to 
the brain from elsewhere,  such as the peripheral arterial or venous system (e.g. via patent foramen 
ovale) The latter is certainly possible through the presence of highly reactive ultra-large VWF 
multimers, hyper-activated platelets and upregulated cell adhesion molecules (through activation of 
the endothelium), all of which would be expected in the vasculature of the brain (Figure 1.7). 
Endothelial dysfunction, particularly vasoconstriction, may occur as a result of direct infection of 
either endothelial cells or smooth muscle cells (Figure 1.8) and may enhance the shear-dependent 
formation of VWF-platelet aggregates in the smaller vessels (Figure 1.10). Neutrophils, circulating in 
high numbers  and in an activated state, may contribute further to in situ thrombus formation in the 
brain through the formation of neutrophil extracellular traps86 (Figure 1.7). The majority of strokes 
being reported in COVID-19 patients are large vessel occlusions18, which is indicative of a 
thromboembolic source, however, in situ thrombosis cannot be ruled out. Given the high incidence 
of myocardial injury (myocarditis, ischaemia, pericarditis etc.) associated with severe COVID-19 
disease/treatment87, secondary stroke in COVID-19 patients may also have a cardioembolic source.  
Is COVID-19 Directly Contributing to Stroke Incidence?
As approximately 65% of observed strokes in COVID-19 patients are conventionally cryptogenic19, it 
may be tempting to prematurely assume a relationship, however, it is very important to emphasise 
that there is no direct evidence for a causal link between COVID-19 and stroke. Standardised case 
reporting and the application of Bradford Hill criteria will be essential in defining causality88.
Thrombotic and cerebrovascular complications are not uncommon in critically ill patients due to 
systemic inflammation, prolonged immobility, intermittent AF, sedation, mechanical ventilation and 
central catheter placement, but can be effectively prevented by prophylactic anti-coagulants89. This 
is not the case in COVID-19 (and the previous SARS outbreak) and a recent retrospective cohort 
study has suggested an incidence of stroke 7-8 times higher in patients hospitalised with COVID-19 
infection compared with those hospitalised by influenza90, supporting the possibility of a SARS-CoV-
2-driven hyper-coagulant state17.  Platform trials of anticoagulant or immunomodulatory therapies in
hospitalised patients with COVID-19 present a unique opportunity for gaining insights into the causal
role of inflammation and thrombosis in stroke risk. However, many of these trials focus on short-
term outcomes and it is unclear whether there would be sufficient power to detect differences in
stroke events, even if incident stroke was recorded as an a priori outcome measure.
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Comorbidities that are common to both COVID-19 and stroke (hypertension, diabetes, obesity etc.) 
may explain, at least some, coincidence of the two pathologies91-93. Obesity, in particular, is 
emerging as a prominent risk factor in the development of severe COVID-19 disease and is generally 
associated with increased incidence and increased severity of respiratory viral infection94, 95. This is 
perhaps unsurprising given the existence of low grade inflammation in obese patients96 which 
undoubtedly contributes to the initiation of ARDS. Notably, the cytokine IL-33 is persistently 
elevated in obese individuals and is capable of stimulating endothelial cells to release pro-coagulant 
tissue factor97 which may expose them to more severe COVID-19 disease and/or stroke. Of course, 
not all COVID-19 patients who go on to have strokes will have these comorbidities, and this is 
especially true of younger patients18. It is in these apparently healthy, young individuals that a causal 
link between COVID-19 and cerebrovascular complications may be the most logical explanation, 
particularly in asymptomatic individuals with significant and undiagnosed inflammation. 
Up until this point, we have discussed the incidence of stroke complicating COVID-19 only in the 
context of the most severe and often critical cases as it does appear to be a delayed complication. It 
could, however, be argued that the strongest case for a causal link would be the incidence of stroke 
in individuals with sub-clinical SARS-CoV-2 infection, which has been identified in a  number of 
cases18. The true extent of community infection is not known due to a failure, in most countries, to 
introduce widespread testing and contact tracing, although this is changing rapidly. It has been 
estimated that in China as many as 86% of cases were undocumented1 and this is likely to be echoed 
in other epicentres of the outbreak and will become apparent when a reliable serological test 
becomes widely implemented. Asymptomatic or mildly symptomatic individuals are also highly 
unlikely to undergo any kind of medical examination, especially in light of the imposed lockdown 
measures. Therefore, we do not yet know the extent of systemic inflammation or the likelihood of 
aberrant coagulation in these mild or asymptomatic patients and whether or not they are at 
increased risk of stroke. An interesting study of infected individuals aboard the Diamond Princess 
cruise ship, one of the earliest clusters outside of China, has given some insight into the extent of 
asymptomatic infection within an isolated, and comprehensively tested population98. Of the 454 
confirmed infections on board, almost half were asymptomatic. Follow up chest imaging, performed 
on 76 of these asymptomatic individuals, revealed a 54% incidence of abnormal CT findings (mostly 
ground-glass opacities). This is not a trivial observation as such abnormalities are indicative of 
established infection and advanced inflammation. Applied to the general population this could 
indicate that as many as 25% of all infected individuals may have undetected inflammation and may 
be at risk of thrombotic complications, including stroke. 
A proven, direct link between COVID-19 and stroke may only arise when a vaccine is deployed which 
then results in a reduced stroke incidence in already at-risk groups, as is thought to be the case with 
the influenza vaccine99. Recent meta-analyses have shown influenza vaccination is associated with a 
reduced risk of stroke; however further prospective studies, particularly large, multicentre 
randomised controlled trials, are required to definitively show this link. Until then, the mere 
possibility of a causal link will undoubtedly require some adaptation of current clinical practises to 
better manage their coincidence. This is likely to include changes to neurovascular imaging 
protocols, thrombolytic administration and the application of mechanical thrombectomy. Some of 
these proposed changes have been outlined  in an international panel report published recently in 
IJS100. A better understanding of the mechanisms underlying a link between COVID-19 and stroke will 
help to adapt these clinical practises further, particularly in regard to the use of thrombolytic, anti-
coagulant and anti-platelet therapies.
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Summary
The SARS-CoV-2 pandemic is by no means the first viral infection to be linked to an increased 
incidence of stroke. Research interest in this phenomenon has peaked upon the emergence of past 
epidemics, giving us some insight into possible mechanisms, but has dissipated as the threat is 
contained (as was the case with SARS and MERS). This represents a missed opportunity to gain 
valuable insight on the general link between infection and stroke.   
Similarly, we may have missed the first opportunity to study the present pandemic as the number of 
new cases in the main epicentres of the outbreak begin to decline. Studies of SARS-CoV-2 so far have 
been generated at a staggering rate, possibly at the expense of scientific rigor. Many have been 
small, case series studies that could be viewed as less insightful than larger, collated clinical datasets.
It is gradually becoming clear from the early epicentres of the outbreak (e.g., China, South Korea) 
that SARS-CoV-2 has not yet been fully contained and, with any potential treatments or vaccine still 
months away, a second wave remains possible. In addition, the implications of any potential causal 
relationship between SARS-CoV-2 and stroke risk on the primary and secondary prevention of stroke 
is yet to be determined. Finally, the impact of COVID-19 combined with seasonal influenza on stroke 
risk remains uncertain. In the meantime, the research community should be preparing to employ 
large systematic clinical studies and establishing animal models of COVID-19 to confirm the causative 
mechanisms by which stroke might occur. Only then will we be prepared for the next viral threat and 
the cerebrovascular risk it may pose.
Page 12 of 
21
International Journal of Stroke
DOI: 10.1177/1747493020943815
Peer Review Version
11
Figure 1. Thromboinflammatory pathways implicated in the pathophysiology of COVID-19 and 
complicating ischaemic stroke. Infection of the lower respiratory tract begins with the binding of 
SARS-CoV-2 to angiotensin converting enzyme 2 (ACE2) on the surface of type II alveolar 
pneumocytes (1). The immediate type I interferon response recruits macrophages, monocytes and 
neutrophils to the alveoli. Propagation of the innate immune response is directed by Th1 and Th17 
CD4+ T cells (2) as neutrophils and pro-inflammatory monocytes are targeted to the site of infection 
(3). Endothelial activation, by either the inflammatory environment or by direct viral infection, 
upregulates key cell adhesion molecules allowing further infiltration of pro-inflammatory 
monocytes, cytotoxic T cells and activated neutrophils (4).  Endothelial activation also elicits tissue 
factor release, endovascular recruitment of neutrophils releasing neutrophil extracellular traps 
(NETs) (4) and von Willebrand factor (VWF) exocytosis from Weibel Palade bodies (5) all of which 
contribute to the development of microvascular thrombosis. These local immune and pro-coagulant 
responses may result in systemic release of multiple cytokines and chemokines and ultra large VWF 
multimers, hyper-activation of circulating platelets and the embolization of VWF/platelet-rich 
thrombi (6). Increased pro-inflammatory and pro-coagulant factors in the plasma could be sufficient 
for in situ thrombus formation in the cerebral vasculature (7) and this may be exacerbated by 
infection and/or activation of the cerebral endothelium and local release of VWF and tissue factor 
(8). Endothelial activation would be expected to facilitate recruitment of neutrophils, monocytes and 
macrophages to the vessel lumen and induce a local inflammatory response in the surrounding brain 
parenchyma thereby polarising microglia (9). Small vessel occlusion, by thromboemboli or by in situ 
thrombosis due to endothelial dysfunction, causes hypoperfusion of brain tissue (10). Ultimately, 
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this combination of tissue hypoperfusion and the pro-inflammatory action of infiltrating and brain 
resident immune cells is the origin of stroke brain injury (11).
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